Compare Revvity Inc (RVTY) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Tyson Foods, Inc. — how do they compare? Revvity Inc trades at $116.57 (market cap $12.91B), while Tyson Foods, Inc. trades at $56.18 (market cap $19.85B). The key difference: Tyson Foods, Inc. is the larger of the two by market cap, and Tyson Foods, Inc. pays the higher dividend (3.62%). Which is the better fit depends on your goals.
| RVTY | TSN | |
|---|---|---|
Market Cap | $12.91B | $19.85B |
Sector | Technology | Consumer Staples |
52-Week High | $117.75 | $68.75 |
52-Week Low | $82.26 | $50.72 |
Enterprise Value | $15.23B | $27.12B |
Dividend Yield | 0.24% | 3.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Tyson Foods (TSN) trades at $55.85, down 2.29% today, reflecting bearish technical signals and mixed fundamentals. Recent Q3 2026 earnings of $0.99 per share beat estimates, but revenue missed expectations amid declining volumes. The company faces headwinds from persistent losses in its beef segment, though chicken and prepared foods remain profitable. Analyst consensus is a 'Buy' with a $68.50 price target, suggesting significant upside potential from current levels.
The outlook hinges on Tyson's ability to stabilize beef margins while leveraging strength in other segments. Investment appeal lies in its low P/S ratio of 0.36 and dividend yield, but risks include volatile commodity costs and execution challenges. Near-term performance will depend on Q3 2026 results and management's guidance update.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
